Piper Sandler downgraded Tourmaline Bio (TRML) to Neutral from Overweight with a price target of $48, down from $65, after the company agreed to be acquired by Novartis (NVS) for $1.4B in cash, or $48 per share.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRML:
- Tourmaline Bio downgraded to Neutral from Buy at H.C. Wainwright
- Tourmaline Bio downgraded to Hold from Buy at Truist
- Tourmaline Bio downgraded to Neutral from Buy at Chardan
- Tourmaline Bio downgraded to Hold from Buy at Jefferies
- Nebius enters AI pact with Microsoft, Teck to combine with Anglo: Morning Buzz